Larry Norton

发表

Targeting stressor-induced dysfunctions in protein-protein interaction networks via epichaperomes.

G. Chiosis, S. Ginsberg, Sahil Sharma, 2022, Trends in pharmacological sciences.

Global Oncology Medical Diplomacy Working Group Inaugural Meeting: Defining Worldwide Barriers to Germline Genomics in Cancer Prevention and Management

G. Abou-Alfa, Larry Norton, 2023, Annals of global health.

Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33

P. Gregersen, A. Clark, A. Olshen, 2008, Proceedings of the National Academy of Sciences.

Gene interaction network analysis in multiple myeloma detects complex immune dysregulation associated with shorter survival

Anish K. Simhal, J. Deasy, A. Tannenbaum, 2023, bioRxiv.

Cancer heterogeneity is defined by normal cellular trade-offs

Kevin A. Murgas, J. Deasy, A. Tannenbaum, 2023, bioRxiv.

The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress.

H. Scher, H. Thaler, N. Kemeny, 1994, European journal of cancer.

Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors.

B. Taylor, M. Berger, E. Papaemmanuil, 2023, JCO precision oncology.

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.

R. Bast, L. Norton, C. Desch, 1996, Journal of the National Cancer Institute.

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

M. Berger, J. Reis-Filho, L. Norton, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening.

M. Skolnick, F. Couch, S. Ingles, 1995, JAMA.

Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families

D. B. Berman, F. Couch, T. Rebbeck, 1996, Nature Medicine.

BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing.

K Offit, A Oliphant, S. Loader, 1997, JAMA.

Germline BRCA1 185delAG mutations in Jewish women with breast cancer

K Offit, A Schluger, M. Skolnick, 1996, The Lancet.